Third Annual Scripps Cardiomyopathy and Cardio-Oncology Symposium
The Role of Screening Tests in Cardiomyopathy: When to Order Genetic Tests or Screen for Arrhythmia
Dr. Ajay Srivastava reviews classifications of cardiomyopathies and the role of genetics when determining appropriate screening for patients.Cardiomyopathy and Cardio-Oncology Symposium: Case Presentations and Panel Discussion - Part 1
Faculty review real-life cases from their practice and answer questions from course participants (session 1 of 2).Beyond Echocardiography: The Role of Multimodality Cardiac Imaging
Dr. Juan Lopez-Mattei discusses the efficacy of multimodality cardiac imaging in diagnosing and identifying cardiomyopathies.Juan Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR
Co-Director, Cardiac Radiology ServicesDepartment of Diagnostic Radiology
Associate Professor of Cardiology and Diagnostic Imaging
The University of Texas MD Anderson Cancer Center
Houston, Texas
Cardiomyopathy and Cardio-Oncology Symposium: Case Presentations and Panel Discussion - Part 2
Faculty review real-life cases from their practice and answer questions from course participants (session 2 of 2).Course Overview
The Scripps Cardiomyopathy and Cardio-Oncology Symposium is designed to provide a comprehensive, case-based curriculum that addresses important clinical topics relevant to cardiomyopathy and cardiovascular health of cancer survivors. Cardio-oncology is a growing field that has great importance as newly developed cancer treatments improve cancer survival rates but can be associated with cardiovascular toxicities. Cardiac amyloidosis, a burgeoning disease with exciting new treatments will also be discussed.
Educational Objectives
- Assess the risks of oncologic treatment-related cardiac dysfunction for patients who have undergone therapy for cancer.
- Implement strategies for early detection, correction of cardiac risk factors, and close and long-term cardiac monitoring in order to reduce the effects of cardiotoxicity for patients who are at risk of cancer treatment-related cardiac dysfunction.
- Discuss the latest diagnosis and treatment options available for cardiac amyloidosis.
- Evaluate multi-modality imaging such as cardiac magnetic resonance (MR), echocardiography, and nuclear imaging including positron emission tomography (PET) scanning in the diagnosis and follow-up of cardiomyopathy.
Target Audience
- Cardiologists
- Oncologists
- Internists
- Nurse Practitioners
- Physician Assistants